3个月新辅助雄激素剥夺联合125I粒子经会阴前列腺近距离放疗后联合或不联合9个月辅助内分泌治疗的中危前列腺癌患者的3期多中心随机对照试验(SHIP0804)十年结局
SHIP0804是一项多中心、开放标签、3期随机对照试验,纳入421例中危前列腺癌患者,在3个月新辅助雄激素剥夺治疗(ADT)和125I经会阴前列腺近距离放疗(TPPB)后随机接受9个月辅助内分泌治疗(AHT)或不接受AHT。中位随访超过11年,10年生化无进展生存率AHT组82.9% vs 非AHT组78.4%(P=0.51),总生存和临床无进展生存两臂相当;AHT组≥3级不良事件发生率为5.4%,非AHT组为1.4%。结论认为加用9个月AHT未改善长期结局,AHT不应被视为该人群的标准治疗。
要点
- 中位随访超过11年,10年生化无进展生存率AHT组82.9% vs 非AHT组78.4%(P=0.51)。
- 总生存和临床无进展生存两臂相当,两组均无前列腺癌死亡。
- ≥3级不良事件AHT组5.4% vs 非AHT组1.4%。
核心结论
- 在3个月新辅助ADT和TPPB后加用9个月AHT未改善中危前列腺癌患者的长期结局。
- 这些发现提示中等疗程AHT可能未带来实质性获益,因此不应被视为该中危前列腺癌人群的标准治疗。
研究设计与样本
- 多中心、开放标签、3期随机对照试验(SHIP0804),421例中危前列腺癌患者随机分配至9个月AHT组(AHT臂)或无AHT组(非AHT臂),均在3个月新辅助ADT和TPPB之后。
- 主要终点为生化无进展生存,次要终点包括总生存和临床无进展生存;治疗后36个月的前列腺活检结果在相关性研究(SHIP36B)中评估。
主要发现
- 中位随访超过11年,10年生化无进展生存率AHT组82.9% vs 非AHT组78.4%(P=0.51)。
- 在随机化时年龄、基线前列腺特异性抗原水平、临床分期、Gleason分级分组、美国国家综合癌症网络中危因素数量和前列腺体积等关键预后指标方面结果一致。
- 总生存和临床无进展生存等次要终点两臂相当。
- ≥3级不良事件发生率AHT组5.4% vs 非AHT组1.4%。
- TPPB后36个月前列腺活检中,仅3.1%的受检患者残留肿瘤阳性;两组均无前列腺癌死亡。
临床怎么用
- 原文结论指出,加用9个月AHT未改善长期结局,中等疗程AHT可能未带来实质性获益,不应被视为该中危前列腺癌人群的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the effects of adjuvant hormonal therapy (AHT) on time to event after neoadjuvant androgen deprivation therapy (ADT) and 125I-transperineal prostate brachytherapy (TPPB), compared with neoadjuvant ADT and TPPB only, in patients with intermediate-risk prostate cancer (IRPC). METHODS AND MATERIALS: In this multicenter, open-label, phase 3 randomized controlled trial (SHIP0804), 421 patients with IRPC were randomly assigned to either 9-month AHT (AHT arm) or no AHT (non-AHT arm) after 3 months of neoadjuvant ADT and TPPB. The primary endpoint was biochemical progression-free survival, and secondary endpoints included overall survival and clinical progression-free survival. Prostatic biopsy results 36 months after treatment were evaluated in a correlative investigation (SHIP36B). RESULTS: With a median follow-up of over 11 years, the 10-year biochemical progression-free survival rates were comparable: 82.9% in the AHT group and 78.4% in the non-AHT group (P = .51). Results were consistent across key prognostic indicators such as age at randomization, baseline prostate-specific antigen level, clinical stage, Gleason grade group, number of National Comprehensive Cancer Network intermediate-risk factors, and prostatic volume. The secondary endpoints, including overall survival and clinical progression-free survival, were also comparable between the 2 arms. Grade 3 or higher adverse events occurred in 5.4% and 1.4% of patients in the AHT and non-AHT arms, respectively. At 36-month post-TPPB prostate biopsy, only 3.1% of biopsied patients tested positive for residual tumors. There were no deaths due to prostate cancer in either group. CONCLUSIONS: Adding 9-month AHT to TPPB after 3-month neoadjuvant ADT did not improve long-term outcomes in patients with IRPC. These findings suggest that moderate-term AHT may not offer substantial benefits and thus should not be considered a standard treatment in this population with IRPC.
引用
- Fukuokaya W, Miki K, Aoki M, et al. Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39551103. doi:10.1016/j.ijrobp.2024.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。